Clinical trial · Interventional
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma
NCT02537925CI-TRIAL-00019027unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Celecoxib | Drug | Celecoxib | ALIAS |
| Concurrent Radiotherapy | Radiation | — | UNRESOLVED |
| Nedaplatin | Drug | Nedaplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- concurrent_radiochemotherapy
- description
- Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
- interventionNames
- Drug: Nedaplatin
- Radiation: Concurrent Radiotherapy
- type
- EXPERIMENTAL
- label
- celecoxib_radiochemotherapy
- description
- Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
- interventionNames
- Drug: Celecoxib
- Drug: Nedaplatin
- Radiation: Concurrent Radiotherapy
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion criteria: * Patients with NPC newly diagnosed by histopathology, and without radiotherapy or chemotherapy before the clinical trial * Patients with measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) criteria * With the Eastern Cooperative Oncology Group Performance Status (ECOG PS) as 0-1 score * Serum hemoglobin ≥10gm/dL, platelet ≥100000/μL, neutrophil granulocyte absolute counting is 1500/μL * Serum creatinine ≤1.25 times of upper normal limit (UNL), creatinine clearance rate ≥ 60 ml/min * Serum bilirubin ≤ 1.5times of UNL, serum aspartate aminotransferase (AST) or glutamic-oxaloacetic transaminase(GOT)≤ 2.5 times of UNL, serum alanine aminotransferase (ALT) or glutamic-pyruvic transaminase (GPT) ≤ 2.5 times of UNL, alkaline phosphatase≤5 times of UNL * The estimate overall survival (OS)\> 6 months * With formal informed consent forms signed. Exclusion criteria: * With symptomatic brain/bone metastases, * With cognitive impairment or other malignancies * With any contraindications for radiotherapy and chemotherapy (such as active phase of infection, myocardial infarction within 6 months, symptomatic heart disease, including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmias, in current immunosuppressive therapy) * Current pregnancy, lactating women or women with fertility but don't take contraceptive measures yet * With severe bone marrow dysfunction * With bleeding tendency * With abuse of drugs or alcohol addicts * Who may have III-IV type of allergic reactions to any treatment in this study * With termination of trial because of intolerable toxicity, other study drugs using during the clinical study, or unwilling to continue the treatment.
References
Publications (2)
- BACKGROUNDSoo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, Tan KB, Low JS, Lai YF, Mow B, Hsu S, Loh KS, Tan L, Tan P, Goh BC. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol. 2006 Nov;17(11):1625-30. doi: 10.1093/annonc/mdl283. Epub 2006 Sep 28. PMID 17008411
- BACKGROUNDMohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin +/- low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial. J Cancer Res Ther. 2011 Oct-Dec;7(4):442-7. doi: 10.4103/0973-1482.92013. PMID 22269407